Invests in
Locations:
Min Investment:
$10,000,000.00Max Investment:
$50,000,000.00Target Investment:
$25,000,000.00
Skills
Education
- YU
- YU
- YU
- IU
Lists including Peter
Work Experience
2019
Partner, President
2023
Partner, Chief Development Officer
2022 - 2023
Senior Managing Director, Head of Asset Development and Financing
2021 - 2022
Senior Managing Director, Head of Company Creation
2019 - 2021
2019
Board Executive Director
2019
Chief Executive Officer
2022 - 2022
Founding Chief Executive Officer
2019 - 2021
2018 - 2019
Senior Principal
2018 - 2019
Peter Fong joined Flagship Pioneering as Senior Principal on Flagship's innovation team in 2018 where he focused on company creation. His responsibilities included leading a team of Flagship entrepreneurial scientists to create first-in-category biotech companies.
iCEO, Harbinger Health
2018 - 2019
iCEO, FL66
2018 - 2019
iCEO, FL54
2018 - 2019
iCEO, FL60
2018 - 2019
2014 - 2018
Associate Director, Oncology Business Development, Genentech Partnering
2016 - 2018
Associate Director of Oncology Business Development in the Genentech Partnering Group in South San Francisco. Responsible for sourcing, screening, evaluating, and acquiring new therapeutics to build the company's oncology pipeline.
Senior Manager, Oncology Business Development, Genentech Partnering
2014 - 2016
2009 - 2014
New Ventures and Business Development
2009 - 2014
Launched and lead Memorial Sloan-Kettering Cancer Center’s (MSKCC’s) New Ventures and Business Development unit.
2007 - 2009
Co-Founder and VP of R&D
2007 - 2009
Co-invented novel nanoparticles for targeted drug delivery, and used technology to build oncology-based biotech company spun out of Yale University. Carigent's IP was licensed by Bind Therapeutics.
1998 - 2007
James Hudson Brown — Alexander Brown Coxe Postdoctoral Fellow
2003 - 2007
Nanoparticle drug delivery research for therapeutic applications and tissue engineering. Work resulted in more than 10 issued or pending patents, some of which have been licensed to 6 biotech or pharmaceutical companies, including Bind Therapeutics, Amgen, and Pfizer.
Graduate Student Research Assistant
1998 - 2003
Developed novel tissue-like biomaterials to study the effects of radiation in tissue for oncology radiotherapy applications. The central approach involved evaluating free-radical induced polymerization and its effect on NMR relaxation.
1995 - 1998
Chemist
1995 - 1998
Worked on the discovery and development of novel block co-polymers for high-heat applications.